USE OF N-MYRISTOYL TRANSFERASE (NMT) INHIBITORS IN THE TREATMENT OF CANCER, AUTOIMMUNE DISORDERS, AND INFLAMMATORY DISORDERS

摘要

The use of N-myristoyl- transferase (NMT) inhibitors in the treatment of cancer, autoimmune disorders, and inflammatory disorders is disclosed. With respect to cancer, the preferred cancer to be treated is B-cell lymphoma, and the NMT used is PCLX-001 (DDD86481, CAS RN 1215011-08-7). Preferred NMT inhibitors for the treatment of autoimmune and inflammatory disorders include the aforementioned PCLX-001, PCLX-002 (DDD85646, CAS RN 1215010-55-10), and IMP-1088 (CAS RN 2059148-82-0), and the disorders to be treated include rheumatoid arthritis, asthma, gastritis, colitis, and other digestive and respiratory ailments.